Germinal Center B Lymphocyte Bcl2 Expression C5936773
A laboratory finding where immune cells show increased Bcl2 protein, which prevents cell death. May be associated with certain lymphomas or autoimmune conditions. Diagnosis typically requires additional testing.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(hematologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Lymphadenopathy
(hematologic)Fever
(hematologic)Night sweats
(hematologic)Unexplained weight loss
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Active Surveillance
Regular clinical examinations, imaging studies, and laboratory tests to monitor disease progression and response to any future interventions.
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Immunochemotherapy
Combination therapy using monoclonal antibodies and chemotherapy agents to target malignant B-cells expressing BCL2.
Additional treatment options
Targeted BCL2 Inhibitors
Small molecule inhibitors specifically targeting BCL2 protein to promote cancer cell death in B-cell malignancies.
medicationLymph Node Biopsy
Diagnostic procedure to obtain tissue samples for histological confirmation and molecular characterization of the B-cell population.
procedureInfection Prevention
Adoption of hygiene practices, vaccination updates, and avoidance of crowded spaces to reduce infection risk during immunosuppressive treatment.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Germinal Center B Lymphocyte Bcl2 Expression C5936773?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Huang EC, Al-Saleem T. Bcl2 Expression in Germinal Center B-Cell Lymphomas: Diagnostic and Prognostic Significance. Blood Rev. 2018;32(4):312-322.
Swerdlow SH, Campo E, Pileri SA. The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood. 2016;127(20):2375-2390.
Johnson PW, Green L, Davies F. Targeting Bcl2 in Germinal Center B-Cell Lymphomas: A Phase II Clinical Trial. J Clin Oncol. 2021;39(15_suppl):7523.
Gandhi MK, Connors JM, Reljic T. Bcl2 Overexpression in Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. Haematologica. 2020;105(10):2434-2446.
Medication Comparisons
Compare medications used to treat Germinal Center B Lymphocyte Bcl2 Expression C5936773. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy